Initially reserved for only the most complex of tasks, robots have become the status quo in many surgical indications.
Approximately 20% of surgeries performed in the US are done with robots and an ever-increasing number of academic papers are...
In Times Of Adversity, Surgical Robot Developers Must Remain Sharp
Harsh economic conditions and increased competition are dictating that surgical robotics companies must quickly adopt new commercial strategies. In Vivo speaks to key players in the space to learn more.
More from Business Strategy
More from In Vivo
• By
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
• By
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.